Engineered immune cells take on lupus nephritis

NCT ID NCT07517536

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells causing kidney damage. Fourteen adults will receive a single infusion after a short chemotherapy prep, and researchers will monitor safety and kidney response for up to a year, with long-term follow-up for 15 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CHT105 (allogeneic CAR-T cells targeting CD19 and CD70)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat lupus nephritis, potentially reducing kidney damage and need for long-term medication.
What could go wrong
This is a very early, small trial with only 14 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.